Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C

Immunological Reviews

Volumn 174, Issue , 2000, Pages 77-89

  Valiante, Nicholas M ^a   D'Andrea, Annalisa ^a   Crotta, Stefania ^a   Lechner, Franziska ^b   Klenerman, Paul ^b   Nuti, Sandra ^a   Wack, Andreas ^a   Abrignani, Sergio ^a  

^a CHIRON VACCINES   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD81 ANTIGEN;

ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; CELL DEATH; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATORY CELL; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRCULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0034071451     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0528.2002.017417.x     Document Type: Review

References (71)

1. 1. Calne RY, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-476.
2. 2. Calne R, Davies H. Organ graft tolerance: the liver effect. Lancet 1994;343:67-68.
3. 3. Starzl TE, Murase N, Thomson A, Demetris AJ. Liver transplants contribute to their own success. Nat Med 1996;2:163-165.
4. 4. Starzl TE, Murase N, Thomson AW, Trucco M, Rao A. Immunity and tolerance are related, and governed by antigen migration and localization. Transplant Proc 1999;31:1406-1411.
5. 5. Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol Med Today 1998;4:116-121.
6. 6. Roitt I, Delves P, eds. Encyclopedia of immunology. San Diego: Academic Press; 1992.
7. 7. Bianchi L. Liver biopsy interpretation in hepatitis. Pathol Res Pract 1983;178:180-213.
8. 8. Ganong WF. Review of medical physiology. Los Altos (CA): Lange Medical Publications; 1975.
9. 9. Markin RS. Hepatitis from non-hepatotropic viruses. In: Goldin RD, Thomas HC, Gerber MA, eds. Pathology of viral hepatitis. New York: Oxford University Press; 1998. p. 115-138.
10. 10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
11. 11. World Health Organization. Hepatitis C viruses Wkly Epidemiol Rec 1997;72:65.
12. 12. Houghton M. In: Fields BN, Knipe DM, Howley PM, eds. Philadelphia (PA) Lippincott-Raven; 1996. p. 1035-1058.
13. 13. Hoofnagle JH. Hepatitis C: clinical spectrum of disease. Hepatology 1997;26:15S-20S
14. 14. McHutchison JG, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
15. 15. Chien DY, et al. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci USA 1992;89:10011-10015.
16. 16. Farci P, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
17. 17. Farci P, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-7796.
18. 18. Rosa D, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996;93:1759-1763.
19. 19. Ishii K, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998;28:1117-1120.
20. 20. Pileri P, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
21. 21. Levy S, et al. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89-109.
22. 22. Berditchevski F, Zutter MM, Hemler ME. Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell 1996;7:193-207.
23. 23. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992;149:2841-2850.
24. 24. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-149.
25. 25. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-1495.
26. + T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 1998;28:3448-3455.
27. 27. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568-574.
28. 28. Koziel MJ, et al. Intra-hepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344.
29. 29. Erickson AL, et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993;151:4189-4199.
30. 30. Koziel MJ, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321.
31. 31. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996;98:1432-1440.
32. + T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis. C. J Exp Med 1993;178:17-24.
33. 33. Botarelli P, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587.
34. 34. Missale G, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin invest 1996;98:706-714.
35. 35. Diepolder HM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clerance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
36. 36. Nelson DR, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481.
37. + T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999;162:6681-6689.
38. 38. Cooper S, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
39. 39. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
40. 40. Murali-Krishna K, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
41. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
42. 42. Gallimore A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383-1393.
43. + T cells. Proc Natl Acad Sci USA 1999;96:8597-8602.
44. + T cells in chronic HIV infection are antigen specific. J Exp Med 1998;188:785-790.
45. 45. Ogg GS, et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol 1999;73:9153-9160.
46. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-5697.
47. 47. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
48. 48. Unutmaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 1994;180:1159-1164.
49. 49. Abrignani S. Bystander activation by cytokines of intra-hepatic T cells in chronic viral hepatitis. Semin Liver Dis 1997;17:319-322.
50. 50. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 1998;279:1737-1740.
51. 51. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
52. 52. Porcelli SA, Brenner MB. 1997. Antigen presentation: mixing oil and water. Curr Biol 7:508-511.
53. 53. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359-393.
54. 54. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-799.
55. 55. Valiante NM, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-751.
56. 56. Ljunggren H, Kärre K. In search of the Missing Self. Immunol Today 1990;11:237-244.
57. 57. Valiante NM, Lienert K, Shilling HG, Smits BJ, Parham P. Killer cell inhibitory receptors: keeping pace with class I evolution. Immunol Rev 1997;155:155-164.
58. 58. Phillips JH, Gumperz JE, Parham P, Lanier LL. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 1995;268:403-405.
59. 59. D'Andrea A, Chang C, Phillips JH, Lanier LL. Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles. J Exp Med 1996;184:789-794.
60. + T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996;93:12433-12438.
61. 61. D'Andrea A, Lanier LL. Killer cell inhibitory receptor expression by T cells. Curr Top Microbiol Immunol 1998;230:25-39.
62. 62. Speiser DE, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999;190:775-782.
63. 63. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-562.
64. 64. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V α 24-J α Q/V β 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8-T cells. J Exp Med 1994;180:1171-1176.
65. 65. Prussin C, Foster B. TCR V α 24 and V β 11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J Immunol 1997;159:5862-5870.
66. - T cells. J Exp Med 1997;186:109-120.
67. + T lymphocytes. Science 1995;268:863-865.
68. + cells in the liver of mice. J Exp Med 1994;180:699-704.
69. + natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999;163:2314-2321.
70. 70. Brodsky FM. Stealth, sabotage and exploitation. Immunol Rev 1999;168:5-11.
71. 71. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-110.